Navigation Links
The Scripps Research Institute Names Michael A. Marletta as President
Date:2/25/2011

LA JOLLA, Calif., Feb. 25, 2011 /PRNewswire/ -- Renowned biochemist Michael A. Marletta, PhD, has been named by the Board of Trustees today as the next president of The Scripps Research Institute, effective January 1, 2012. He will succeed President Richard A. Lerner, MD, who has led the institution for 25 years.

Image available at: http://www.scripps.edu/news/press/images/20110220_marletta/marletta_m.jpg

Marletta, past Chair of the Department of Chemistry, Co-Director of the Chemical Biology Graduate Program, Aldo DeBenedictis Distinguished Professor of Chemistry and Professor of Biochemistry in the Department of Molecular and Cell Biology at the University of California (UC), Berkeley, will join the Scripps Research faculty on July 1, 2011, and become President and CEO January 1, 2012.

"We are thrilled Michael is assuming this important role," said Dick Gephardt, President/CEO of Gephardt Government Affairs and Lead Trustee of the Scripps Research Board of Trustees. "We are confident Michael's leadership and vision will ensure the Institute's continued preeminence in biomedical research and graduate education."

"I am honored to be named to lead one of the premier research institutions in the world," said Marletta. "Richard Lerner's leadership over the past 25 years has been nothing short of brilliant. His accomplishments as President coupled with a long and distinguished research career, are simply amazing. In addition to my excitement about being asked to serve as president, I am thrilled about moving my research program to Scripps Research and working with my new Scripps Research colleagues to push forward the Institute's legacy of creating knowledge, improving healthcare, and educating the next generation of scientists."

Like The Scripps Research Institute as a whole, Marletta—a former recipient of the prestigious MacArthur Fellowship—has focused his research on the intersection of chemistry and biology. He is acknowledged as a pioneer in discovering the role of nitric oxide, a critical player in communication between cells.

Lerner, who will continue to lead his groundbreaking research program at the Institute after his tenure as president, said, "Please join me in welcoming Michael Marletta to Scripps Research. I have great confidence in his abilities and look forward to working with him during the transition and beyond. Given Michael's expertise, we can be secure in the knowledge that the flagship programs of the Institute will continue to thrive."

"We are extremely pleased to announce Michael Marletta as the next president of The Scripps Research Institute," said Lawrence C. Horowitz, MD, member of the Board of Trustees and Chair of the Presidential Search Committee, who spoke on behalf of the Committee as a whole. "His extensive and distinguished professional background, passion for science and education, and ability to lead strategically embody the ideal mix of talent and vision to carry Scripps Research into the future."

Horowitz added that the Board is deeply grateful to Lerner for his extraordinary contributions, and expresses confidence Lerner and Marletta will work together to assure a seamless transition.

Celebrations welcoming Marletta, honoring Lerner, and marking the 50th anniversary of the institute's focus on biomedical research are planned throughout the year.

About Michael Marletta

Michael A. Marletta was born in Rochester, New York, in 1951. After completing an AB at the State University of New York (SUNY), Fredonia, (1973), a PhD from UC San Francisco (1978) with George L. Kenyon, and a postdoctoral fellowship at the Massachusetts Institute of Technology (MIT, 1978 - 80) with Christopher T. Walsh, he joined the faculty at MIT as assistant professor in 1980. He was promoted to associate professor in 1986. In 1987, he moved to the University of Michigan as associate professor in its College of Pharmacy and Medical School. In 1991, he was promoted to professor and appointed the John G. Searle Professor of Medicinal Chemistry. In 1997, he was named to the Howard Hughes Medical Institute (HHMI). Marletta moved to UC Berkeley in 2001. At that time, he also received joint appointments at UC San Francisco and Lawrence Berkeley National Laboratory.

He is the recipient of dozens of awards and honors, including the MacArthur Foundation Fellowship (1995); election to the Institute of Medicine (1999); Distinguished Faculty Achievement Award, University of Michigan (2000); election to the American Academy of Arts and Sciences (2001); and election to the National Academy of Sciences (2006).

Marletta currently serves on the editorial boards of ACS Chemical Biology and the Proceedings of the National Academy of Sciences, as well as other journals. A member of the HHMI Science Review Board and the Fredonia College Foundation Board of Directors, he also serves on the scientific advisory boards of Lycera, Viamet Pharmaceuticals, and N30 Pharma, and is a co-founder of Omniox, Inc.

Marletta is married to Margaret Gutowski and they have a 15 year old son, Matthew.  

About The Scripps Research Institute

The Scripps Research Institute is one of the world's largest independent, non-profit biomedical research organizations. Headquartered in La Jolla, California, Scripps Research is internationally recognized for its discoveries in immunology, molecular and cellular biology, chemistry, neuroscience, and vaccine development, as well as autoimmune, cardiovascular, and infectious disease. The institute also includes a campus in Jupiter, Florida, where scientists focus on basic biomedical science, drug discovery, and technology development. Scripps Research currently employs approximately 3,000 scientists, staff, postdoctoral fellows, and graduate students on its two campuses. The institute's graduate program, which awards Ph.D. degrees in biology and chemistry, is ranked among the top ten such programs in the nation. For more information, see www.scripps.edu.

This news release was issued on behalf of Newswise(TM). For more information, visit http://www.newswise.com.


'/>"/>
SOURCE Scripps Research Institute
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
2. Quest Diagnostics Brings Genetic Testing for Plavix(R) Response to Coronary Stent Patients at Scripps Health
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
5. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
6. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
7. Video: New Research Discovers Independent Brain Networks Control Human Walking
8. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
9. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
10. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
11. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice ... "Film editors can give their videos a whole new perspective by using the ... of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
Breaking Medicine News(10 mins):